Company profile
TuHURA Biosciences, Inc./NV
NASDAQ:HURABiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| PEMBROLIZUMAB | phase3 | — | 263 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06940440 | phase1 | recruiting | 2025-10-01 | 2026-05-31 | TuHURA Biosciences, Inc. | IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC) |
| NCT04925713 | phase1 | completed | 2021-06-10 | 2021-10-07 | TuHURA Biosciences, Inc. | IFx-Hu2.0 for the Treatment of Patients With Skin Cancer |
| NCT04160065 | phase1 | completed | 2020-03-03 | 2023-10-19 | TuHURA Biosciences, Inc. | Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers |
| NCT06947928 | phase2_3 | recruiting | 2025-12-11 | 2027-03-31 | TuHURA Biosciences, Inc. | Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma |
| NCT03655756 | — | completed | 2018-11-05 | 2020-07-10 | TuHURA Biosciences, Inc. | pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma |
FDA applications (0)
No records yet.